Telesis Bio (TBIO) Stock Price, News & Analysis

Company Overview

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.61 to $3.18
• 50-Day Range: $1.35 to $5.50
• 52-Week Range: $1.27 to $22.40
• Volume: 686,892 shs
• Average Volume: 375,387 shs
• Market Capitalization: $5.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Telesis Bio Stock Analysis - MarketRank™

Telesis Bio scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Telesis Bio.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Telesis Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telesis Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Telesis Bio has a P/B Ratio of 22.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.69% of the float of Telesis Bio has been sold short.

Short Interest Ratio / Days to Cover

Telesis Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telesis Bio has recently decreased by 51.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telesis Bio does not currently pay a dividend.

Dividend Growth

Telesis Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.69% of the float of Telesis Bio has been sold short.

Short Interest Ratio / Days to Cover

Telesis Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telesis Bio has recently decreased by 51.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Telesis Bio has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

Search Interest

3 people have searched for TBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telesis Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.50% of the stock of Telesis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 37.63% of the stock of Telesis Bio is held by institutions.

TBIO Stock Analysis - Frequently Asked Questions

How have TBIO shares performed this year?

Telesis Bio's stock was trading at $7.1820 at the beginning of 2024. Since then, TBIO stock has decreased by 57.0% and is now trading at $3.09.
View the best growth stocks for 2024 here.

How were Telesis Bio's earnings last quarter?

Telesis Bio, Inc. (NASDAQ:TBIO) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($7.03) EPS for the quarter. The company earned $1.55 million during the quarter, compared to the consensus estimate of $6.50 million. Telesis Bio had a negative net margin of 282.58% and a negative trailing twelve-month return on equity of 359.32%.

When did Telesis Bio's stock split?

Telesis Bio's stock reverse split on Thursday, May 9th 2024. The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Telesis Bio IPO?

Telesis Bio (TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

How do I buy shares of Telesis Bio?

Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Telesis Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA) and Johnson & Johnson (JNJ).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:TBIO
• Previous Symbol: NASDAQ:DNAY
• CUSIP: N/A
• CIK: 1850079
• Web: telesisbio.com
• Phone: 858-228-4115
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($28.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-47,720,000.00
• Net Margins: -282.58%
• Pretax Margin: -279.62%
• Return on Equity: -359.32%
• Return on Assets: -50.95%

Debt

• Debt-to-Equity Ratio: 22.76
• Current Ratio: 1.89
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $19.57 million
• Price / Sales: 0.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 21.14

Miscellaneous

• Outstanding Shares: 1,683,000
• Free Float: 1,271,000
• Market Cap: $4.98 million
• Optionable: Optionable
• Beta: 1.73